← Back to Clinical Trials
Recruiting NCT06449794

NCT06449794 Neuropsycatric Disorders Among Children With Systemic Lupus Erythematosus in Sohag University Hospital

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06449794
Status Recruiting
Phase
Sponsor Sohag University
Condition Systemic Lupus Erythematosus
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2024-06-01
Primary Completion 2025-06-01

Eligibility & Interventions

Sex All sexes
Min Age 1 Year
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Anti Phospholipid antibodiesEEG

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2024-06-01 with a primary completion date of 2025-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs, characterized by the production of autoantibodies and the development of tissue injury. The etiology of SLE is partially known, involving multiple genetic and environmental factors. As many as 50% of patients with SLE have neurological involvement during the course of their disease. Approximately 40% of neuropsychiatric SLE (NPSLE) cases are a consequence of the disease itself; other causes of NPSLE are infections, metabolic disorders, and side effects of drugs. The American College of Rheumatology identified 19 neuropsychiatric syndromes in SLE patients that can be divided into central and peripheral nervous system manifestations. Although this classification includes syndromes with no clear pathophysiological mechanism and is not specific for neuropsychiatric events caused exclusively by SLE, it helps the physician to recognize any neurological involvement . The most common clinical manifestations of juvenile neuropsychiatric SLE (NPSLE) are headache, cognitive dysfunction, mood disturbances and seizures. The pathophysiology of juvenile NPSLE is not yet fully known, but immunological and inflammatory factors, such as autoantibodies, cytokine and prothrombotic states are widely described . The of autoantibodies in the onset of specific clinical manifestations has also been recognized. Juvenile NPSLE manifestations are often difficult to diagnose (. Nineteen neuropsychiatric syndromes have been identified associated with SLE, can be divided into central and peripheral manifestations.

Eligibility Criteria

Inclusion Criteria: * The study aims to include all children fulfilling the diagnostic criteria of SLE (The European League Against Rheumatism and The American College of Rheumatology (9)) attending to pediatric rheumatology and immunology clinic at Sohag University Hospitals during the study period. Exclusion Criteria: * Children with other rheumatological disorders.; Neonates (infants \> 1 month) Children with other neuropsychiatric disorders not attributed to SLE ( e.g. infection, metabolic disorders or side effects of drugs).

Contact & Investigator

Central Contact

Amira M Mahmoud, resident

✉ amerah.mahmoud@med.sohag.edu.eg

📞 01098129862

Frequently Asked Questions

Who can join the NCT06449794 clinical trial?

This trial is open to participants of all sexes, aged 1 Year or older, studying Systemic Lupus Erythematosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06449794 currently recruiting?

Yes, NCT06449794 is actively recruiting participants. Contact the research team at amerah.mahmoud@med.sohag.edu.eg for enrollment information.

Where is the NCT06449794 trial being conducted?

This trial is being conducted at Sohag, Egypt.

Who is sponsoring the NCT06449794 clinical trial?

NCT06449794 is sponsored by Sohag University. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology